~~<i id='8422F12E11'><strike id='8422F12E11'><tt id='8422F12E11'><pre id='8422F12E11'></pre></tt></strike></i>~~

Home» explore» focus

focus

author：fashion 2025-09-06 05:29:35 Page View：8

Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks.

“Oh, crap,” Secrist said to herself.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： US recommends Americans reconsider traveling to China due to arbitrary law enforcement, exit bans
Next article： The cancer drug shortage isn’t new — and neither are the solutions

explore

Walensky prepares to leave CDC — and Congress — behind

OutgoingCDCDirectorRochelleWalenskyJIMWATSON/AFPviaGettyImagesRochelleWalensky,theoutgoingdirectorof

Churchill Downs extends trainer Bob Baffert's ban through 2024

TrainerBobBaffertwalksoffthetrackafterhishorseArabianLionwonTheWoodyStephensaheadoftheBelmontStakesh

After affirmative action ruling, medical educators look to 'holistic review'

AnnaMoneymaker/GettyImagesAfterhavingadaytoreadthroughtheSupremeCourt’sdecisiononaffirmativeaction,s

Case highlights the risks of experimental stem cell therapy

Neurons(red)andastrocytes(green)derivedfromhumanneuralstemcellsgrowinginculture.StevenPollard/Wellco